Literature DB >> 10389607

The economic burden of schizophrenia in Canada.

R Goeree1, B J O'Brien, P Goering, G Blackhouse, K Agro, A Rhodes, J Watson.   

Abstract

OBJECTIVE: To estimate the financial burden of schizophrenia in Canada in 1996.
METHOD: Using a prevalence-based approach, all direct health care costs, administrative costs of income assistance plans, and costs of incarceration attributable to schizophrenia were determined. Also included was the value of lost productivity associated with premature mortality and morbidity. In addition to using published papers and documents, direct contact was made with representatives from various provincial and federal programs for estimates of the direct health care and non-health care costs.
RESULTS: The estimated number of persons with schizophrenia in Canada in 1996 was 221,000, with equal distribution between males and females. The direct health care and non-health care cost was estimated to be $1.12 billion in 1996. In addition, another $1.23 billion in lost productivity associated with morbidity and premature mortality was attributable to schizophrenia.
CONCLUSIONS: The total financial burden of schizophrenia in Canada was estimated to be $2.35 billion in 1996. The largest category of cost was morbidity (52%), followed by acute care and psychiatric hospital admissions (14% and 10% respectively). Given the magnitude of these cost estimates, there are large potential cost savings with more effective management and control of this debilitating disease.

Entities:  

Mesh:

Year:  1999        PMID: 10389607     DOI: 10.1177/070674379904400506

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  14 in total

1.  Mental health and primary care.

Authors:  J Arboleda-Flórez; B Saraceno
Journal:  CMAJ       Date:  2001-04-03       Impact factor: 8.262

2.  How to manage the first episode of schizophrenia.

Authors:  S Frangou; P Byrne
Journal:  BMJ       Date:  2000-09-02

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Costs of new atypical antipsychotic agents for schizophrenia: does unrestricted access reduce hospital utilization?

Authors:  Daria O'Reilly; David Craig; Leslie Phillips; Ron Goeree; Jean-Eric Tarride; Patrick Parfrey
Journal:  Healthc Policy       Date:  2007-08

Review 5.  The Societal Cost of Schizophrenia: A Systematic Review.

Authors:  Huajie Jin; Iris Mosweu
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

6.  Overview and emerging trends.

Authors:  Sandeep Grover; Ajit Avasthi; Subho Chakrabarti; Paramanand Kulhara
Journal:  Indian J Psychiatry       Date:  2005-10       Impact factor: 1.759

7.  Cost-effectiveness analysis of ziprasidone versus haloperidol in sequential intramuscular/oral treatment of exacerbation of schizophrenia: economic subanalysis of the ZIMO trial.

Authors:  Fernando Cañas; Víctor Pérez-Solá; Silvia Díaz; Javier Rejas
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

8.  Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada).

Authors:  Soma Ganesan; Mario McKenna; Ric M Procyshyn; Sheldon Zipursky
Journal:  Curr Ther Res Clin Exp       Date:  2007-11

9.  Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada.

Authors:  Laura Lammers; Bree Zehm; Richard Williams
Journal:  BMC Psychiatry       Date:  2013-05-30       Impact factor: 3.630

10.  Expert Canadian consensus suggestions on the rational, clinical use of ziprasidone in the treatment of schizophrenia and related psychotic disorders.

Authors:  Stan Kutcher; Sarah J Brooks; David M Gardner; Bill Honer; Lili Kopala; Alain Labelle; Pierre Lalonde; Ashok Malla; Heather Milliken; Jorge Soni; Richard Williams
Journal:  Neuropsychiatr Dis Treat       Date:  2005-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.